Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Voyager Therapeutics (VYGR) EBT (2016 - 2025)

Voyager Therapeutics (VYGR) has disclosed EBT for 11 consecutive years, with -$27.4 million as the latest value for Q4 2025.

  • Quarterly EBT rose 19.13% to -$27.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$119.6 million through Dec 2025, down 85.86% year-over-year, with the annual reading at -$119.6 million for FY2025, 85.86% down from the prior year.
  • EBT hit -$27.4 million in Q4 2025 for Voyager Therapeutics, up from -$27.8 million in the prior quarter.
  • In the past five years, EBT ranged from a high of $124.7 million in Q1 2023 to a low of -$33.9 million in Q4 2024.
  • Historically, EBT has averaged -$8.5 million across 5 years, with a median of -$22.9 million in 2022.
  • Biggest five-year swings in EBT: crashed 566.69% in 2022 and later skyrocketed 685.15% in 2023.
  • Year by year, EBT stood at $5.1 million in 2021, then plummeted by 566.69% to -$23.6 million in 2022, then soared by 342.34% to $57.2 million in 2023, then plummeted by 159.25% to -$33.9 million in 2024, then increased by 19.13% to -$27.4 million in 2025.
  • Business Quant data shows EBT for VYGR at -$27.4 million in Q4 2025, -$27.8 million in Q3 2025, and -$33.4 million in Q2 2025.